DUOFAG

AXP000234.1 · Phage therapy

Platform
phage cocktail (non-engineered)
Originator
MB Pharma
Sponsor
MB Pharma

Names

NameTypeSource
DUOFAGpreferred name, brandcurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
bacteriophage cocktail against S. aureus and P. aeruginosa
Replication
replicating
Route
topical
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06319235Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®UnknownPhase 1/22023-10-272025-12-3152Bacterial Infections; Pseudomonas Aeruginosa Infection; Staphylococcus Aureus Infection; Surgical Site Infection; Surgical Wound Infection

Recent changes

No changes recorded in its trials yet.

Notes

Phage preparation against Staphylococcus aureus and Pseudomonas aeruginosa for infected surgical wounds; phase 1/2a NCT06319235.

How to cite

DUOFAG (AXP000234.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000234.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.